A wide variety of masses can arise in the maxillary sinuses. Pathologies range from polyps, cysts, and other benign entities to a numb er of malignant processes. One way of evaluatin g a mass in the maxill ary sinus is to obtain a transnasal biop sy from the middl e meatus. However, this technique can be exceedingly diffi cult to perform, depending on the position of the mass. Another way to biopsy such a mass is via the canine fossa approach as describ ed by Draf and Stammb erger .'
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To perform the trans-c anin e-fossa maxillary sinoscopy pro cedure, locate the canin e fossa, which lies bet ween the canine and the first prem olar , and inject the area with a local anesthetic. Place a sinoscopy trocar with sheath (length: 8.5 em ; outer diameter: 5 mm) at the superolateral 
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Apply pressur e wi th a careful to-and-fro rotating movement until the troc ar pen etrates the maxillar y sinus . T he width of the anterior maxill ary wa ll bone wi ll determ ine how much pressure is req uir ed . As the pressure is applied, the surgeon must be careful to prop erly brace himself for the passage of the trocar into the sinus.
O nce the trocar is passed into the sinus, wi thdraw it and leave the sheath in place. Th e sheath allo ws for the passage of a 4-mm telescop e, which can provide a full view of the maxillar y sinus. At this point, use a 0°scop e to visua lize the mass in quest ion. The mass sho uld be cen tered within the sco pe's field (figure, B). W ithout movin g the sheath, withdraw the sco pe , pass a biop sy forc ep s throu gh the shea th, and take the biop sy blind ly (f igure , C ). Wi thdra w the forcep s and re insert the scope to revis ualize the area to co nfirm that the biopsy was taken co rrectly (fig ure, D) . St ammberger writes that with some ex perience , the surgeon should find this to be faster and more effective than usi ng an optica l biopsy forceps.' T wo other adva ntages of thi s meth od are that it all ows the surgeon to biop sy masses in difficult si nus position s and it ca n be performed in an o utpatient se tting.
Prior to any trocar place men t, the surgeon must study the app ropriate sinus rad iographs to determi ne if there are any anatomic var iations of the sinus. T his wi ll help determine the opt ima l an gle for trocar introd uc tion and thereby avo id co mplications.':' If the tro car is placed too inferiorly wi thin the ca nine fossa, it migh t da mage one of the tooth roo ts. If it is placed too medi all y, it might penetrate the antral wall and enter the nasal cav ity .
1 More wo rriso me complications are disruption of the lacrimal duc t and vio lation of the lateral sinus wa ll, which co uld di srup t the so ft tissues of the face . II'the trocar enters the pter ygom axill ary space, it could dama ge the internal maxi llary art ery, the infraorbital nerve , o r branch es of the trigeminal nerve . Finall y, the surgeo n sho uld be most ca reful not to point the trocartoward the orbit because this co uld resul t in blindn ess; it might be he lpful to palpate the infer ior or bital rim during the procedure to rei nforce the lim it of posit ioni ng.
